Elanco Completes AHV Acquisition to Expand Dairy Health Solutions

Elanco Animal Health has completed the acquisition of AHV International, a Netherlands-based innovator in farm animal health, reinforcing its commitment to the growing global dairy industry. The deal expands Elanco’s portfolio of dairy health solutions and provides producers with additional tools designed to improve cow well-being, productivity and sustainability.

According to information released by Elanco, the acquisition is part of the company’s strategy to strengthen its presence in the dairy market at a time when global demand for milk and dairy products continues to rise. The integration brings together Elanco’s scientific expertise, technical teams and global distribution network with AHV’s specialized dairy technologies.

Dr. Ramiro M. Cabral, Executive Vice President of Elanco International, highlighted the strategic value of the transaction. “The AHV addition is a strategic fit for Elanco by providing innovative tools for producers and veterinarians to improve the well-being of dairy cows. AHV’s portfolio meaningfully expands our solutions for sustainability, animal welfare and transition cow health, as well as for retail packaged goods. Together with our dedicated scientific and technical Elanco team, the integration will unite the strengths of both organizations to deliver a comprehensive solution portfolio for our customers,” he said.

The acquisition comes as dairy producers face increasing pressure to improve efficiency while maintaining animal health standards. Industry data cited by the company indicate that disease and mortality account for significant productivity losses in livestock production each year, affecting both profitability and food security.

A key aspect of the acquisition is AHV’s focus on preventive and nutritional health solutions that can be adapted to the needs of individual animals during critical stages of production.

Among the technologies added to Elanco’s portfolio is StopLac, a solution designed to reduce milk production during the dry-off period at the end of a cow’s lactation cycle. This process is considered essential for maintaining animal health and preparing cows for future productivity.

The acquisition also includes AHV’s Quorum Sensing Technology, which uses plant-derived extracts to disrupt biofilm formation. By exposing pathogens to the animal’s natural immune defenses, the technology aims to help cows fight disease more effectively while potentially reducing reliance on antibiotics.

The combined company believes these innovations can support broader industry goals related to animal welfare, sustainable dairy production and responsible antibiotic use. Elanco plans to leverage its international reach to make these technologies available to dairy producers in additional markets around the world.

The transaction reflects a broader trend across the agricultural sector, where companies are investing in technologies that improve efficiency and health outcomes while addressing growing consumer expectations regarding sustainability and food production practices.

For Elanco, the addition of AHV represents more than a portfolio expansion. It strengthens the company’s position in a dairy market that increasingly values preventive health management, productivity gains and solutions that support long-term farm sustainability.